<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03539432</url>
  </required_header>
  <id_info>
    <org_study_id>20-018</org_study_id>
    <nct_id>NCT03539432</nct_id>
  </id_info>
  <brief_title>Exploration of Gemfibrozil as a Treatment for AUD</brief_title>
  <official_title>Exploration of Gemfibrozil as a Treatment for Alcohol Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Mind Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Mind Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the efficacy of the medication gemfibrozil in reducing alcohol&#xD;
      consumption in individuals with an alcohol use disorder who are seeking treatment for&#xD;
      alcohol-related problems. Twenty individuals will be randomized to receive four weeks of&#xD;
      either gemfibrozil or placebo and retrospective reports of alcohol use will be collected&#xD;
      throughout the trial. In addition, brain imaging measures will be collected at baseline and&#xD;
      after two weeks of treatment to determine the effects of gemfibrozil on brain functioning.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funds for the study expired&#xD;
  </why_stopped>
  <start_date type="Actual">May 16, 2018</start_date>
  <completion_date type="Actual">December 30, 2018</completion_date>
  <primary_completion_date type="Actual">December 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Standard Drinks Per Drinking Day</measure>
    <time_frame>Baseline</time_frame>
    <description>Average number of standard drinks consumed on drinking days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Standard Drinks Per Drinking Day</measure>
    <time_frame>2 weeks post baseline</time_frame>
    <description>Average number of standard drinks consumed on drinking days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Standard Drinks Per Drinking Day</measure>
    <time_frame>4 weeks post baseline</time_frame>
    <description>Average number of standard drinks consumed on drinking days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Days Abstinent</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of days of abstinence from alcohol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Days Abstinent</measure>
    <time_frame>2 weeks post baseline</time_frame>
    <description>Percentage of days of abstinence from alcohol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Days Abstinent</measure>
    <time_frame>4 weeks post baseline</time_frame>
    <description>Percentage of days of abstinence from alcohol</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>Gemfibrozil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemfibrozil 600 mg by mouth twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Microcrystalline cellulose powder packaged in capsules identical to the experimental condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemfibrozil 600 MG</intervention_name>
    <description>Gemfibrozil capsules (600 mg) taken twice per day</description>
    <arm_group_label>Gemfibrozil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Microcrystalline cellulose powder packaged in capsules identical to the experimental medication</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. males and females age 18-60 meeting DSM-V criteria for moderate or severe AUD in the&#xD;
             past year&#xD;
&#xD;
          2. interested in cutting down or quitting drinking&#xD;
&#xD;
          3. able to provide voluntary informed consent&#xD;
&#xD;
          4. have at least 4 heavy drinking days (â‰¥ 5 drinks per day for men, and 4 for women) in&#xD;
             the past 30 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. severe liver disease; severe kidney disease; gallbladder disease or gallstones&#xD;
&#xD;
          2. chronic renal or hepatic failure&#xD;
&#xD;
          3. recent pancreatitis&#xD;
&#xD;
          4. insulin-dependent diabetes&#xD;
&#xD;
          5. other urgent medical problems&#xD;
&#xD;
          6. moderately elevated liver function tests (AST or ALT greater than 2 times upper limit&#xD;
             of normal) or elevated creatine kinase (CK)&#xD;
&#xD;
          7. schizophrenia, schizoaffective disorder, Bipolar I disorder, suicidal thoughts in the&#xD;
             last month&#xD;
&#xD;
          8. current moderate or severe other substance use disorder (SUD; except nicotine or&#xD;
             marijuana)&#xD;
&#xD;
          9. active legal problems with the potential to result in incarceration&#xD;
&#xD;
         10. pregnancy or lactation, or child bearing age and not on birth control or not willing&#xD;
             to use other birth control methods (e.g. condoms)&#xD;
&#xD;
         11. current daily use of anti-craving medications, mood stabilizers, benzodiazepines, or&#xD;
             anti-psychotics&#xD;
&#xD;
         12. regularly taking a medication contraindicated for use with gemfibrozil including other&#xD;
             fibrates, statins, repaglinide, or which are believed to interact with gemfibrozil&#xD;
             such as dasabuvir, dabrafenib, loperamide, montelukast, paclitaxel, pioglitazone,&#xD;
             rosiglitazone, colestipol, colchicine and warfarin41,68&#xD;
&#xD;
         13. a history of alcohol withdrawal-induced seizures or delirium tremens (hallucinations,&#xD;
             disorientation) requiring hospital admission during the last ten years&#xD;
&#xD;
         14. a history of moderate or severe traumatic brain injury (TBI; loss of consciousness &gt;30&#xD;
             minutes69)&#xD;
&#xD;
         15. left-handedness&#xD;
&#xD;
         16. any contraindications for MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Mind Research Network</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 16, 2018</study_first_submitted>
  <study_first_submitted_qc>May 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2018</study_first_posted>
  <results_first_submitted>August 31, 2021</results_first_submitted>
  <results_first_submitted_qc>September 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 18, 2021</results_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemfibrozil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT03539432/Prot_SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT03539432/ICF_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gemfibrozil</title>
          <description>Gemfibrozil 600 mg by mouth twice daily&#xD;
Gemfibrozil 600 MG: Gemfibrozil capsules (600 mg) taken twice per day</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Microcrystalline cellulose powder packaged in capsules identical to the experimental condition&#xD;
Placebo oral capsule: Microcrystalline cellulose powder packaged in capsules identical to the experimental medication</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gemfibrozil</title>
          <description>Gemfibrozil 600 mg by mouth twice daily&#xD;
Gemfibrozil 600 MG: Gemfibrozil capsules (600 mg) taken twice per day</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Microcrystalline cellulose powder packaged in capsules identical to the experimental condition&#xD;
Placebo oral capsule: Microcrystalline cellulose powder packaged in capsules identical to the experimental medication</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Standard Drinks Per Drinking Day</title>
        <description>Average number of standard drinks consumed on drinking days</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gemfibrozil</title>
            <description>Gemfibrozil 600 mg by mouth twice daily&#xD;
Gemfibrozil 600 MG: Gemfibrozil capsules (600 mg) taken twice per day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Microcrystalline cellulose powder packaged in capsules identical to the experimental condition&#xD;
Placebo oral capsule: Microcrystalline cellulose powder packaged in capsules identical to the experimental medication</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Standard Drinks Per Drinking Day</title>
          <description>Average number of standard drinks consumed on drinking days</description>
          <units>Drinks per drinking day</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.17" lower_limit="5.57" upper_limit="6.76"/>
                    <measurement group_id="O2" value="8.59" lower_limit="8.59" upper_limit="8.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Standard Drinks Per Drinking Day</title>
        <description>Average number of standard drinks consumed on drinking days</description>
        <time_frame>2 weeks post baseline</time_frame>
        <population>The one participant in the placebo condition dropped out before taking any medication</population>
        <group_list>
          <group group_id="O1">
            <title>Gemfibrozil</title>
            <description>Gemfibrozil 600 mg by mouth twice daily&#xD;
Gemfibrozil 600 MG: Gemfibrozil capsules (600 mg) taken twice per day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Microcrystalline cellulose powder packaged in capsules identical to the experimental condition&#xD;
Placebo oral capsule: Microcrystalline cellulose powder packaged in capsules identical to the experimental medication</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Standard Drinks Per Drinking Day</title>
          <description>Average number of standard drinks consumed on drinking days</description>
          <population>The one participant in the placebo condition dropped out before taking any medication</population>
          <units>Drinks per drinking day</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.12" lower_limit="3.58" upper_limit="4.667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Standard Drinks Per Drinking Day</title>
        <description>Average number of standard drinks consumed on drinking days</description>
        <time_frame>4 weeks post baseline</time_frame>
        <population>The one participant in the placebo condition dropped out before taking any medication</population>
        <group_list>
          <group group_id="O1">
            <title>Gemfibrozil</title>
            <description>Gemfibrozil 600 mg by mouth twice daily&#xD;
Gemfibrozil 600 MG: Gemfibrozil capsules (600 mg) taken twice per day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Microcrystalline cellulose powder packaged in capsules identical to the experimental condition&#xD;
Placebo oral capsule: Microcrystalline cellulose powder packaged in capsules identical to the experimental medication</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Standard Drinks Per Drinking Day</title>
          <description>Average number of standard drinks consumed on drinking days</description>
          <population>The one participant in the placebo condition dropped out before taking any medication</population>
          <units>Drinks per drinking day</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.18" lower_limit="2" upper_limit="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Days Abstinent</title>
        <description>Percentage of days of abstinence from alcohol</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gemfibrozil</title>
            <description>Gemfibrozil 600 mg by mouth twice daily&#xD;
Gemfibrozil 600 MG: Gemfibrozil capsules (600 mg) taken twice per day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Microcrystalline cellulose powder packaged in capsules identical to the experimental condition&#xD;
Placebo oral capsule: Microcrystalline cellulose powder packaged in capsules identical to the experimental medication</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Days Abstinent</title>
          <description>Percentage of days of abstinence from alcohol</description>
          <units>Percentage of abstinent days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="16.7" upper_limit="44.4"/>
                    <measurement group_id="O2" value="32.2" lower_limit="32.2" upper_limit="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Days Abstinent</title>
        <description>Percentage of days of abstinence from alcohol</description>
        <time_frame>2 weeks post baseline</time_frame>
        <population>The one participant in the placebo condition dropped out before taking any medication</population>
        <group_list>
          <group group_id="O1">
            <title>Gemfibrozil</title>
            <description>Gemfibrozil 600 mg by mouth twice daily&#xD;
Gemfibrozil 600 MG: Gemfibrozil capsules (600 mg) taken twice per day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Microcrystalline cellulose powder packaged in capsules identical to the experimental condition&#xD;
Placebo oral capsule: Microcrystalline cellulose powder packaged in capsules identical to the experimental medication</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Days Abstinent</title>
          <description>Percentage of days of abstinence from alcohol</description>
          <population>The one participant in the placebo condition dropped out before taking any medication</population>
          <units>Percentage of abstinent days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" lower_limit="0" upper_limit="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Days Abstinent</title>
        <description>Percentage of days of abstinence from alcohol</description>
        <time_frame>4 weeks post baseline</time_frame>
        <population>The one participant in the placebo condition dropped out before taking any medication</population>
        <group_list>
          <group group_id="O1">
            <title>Gemfibrozil</title>
            <description>Gemfibrozil 600 mg by mouth twice daily&#xD;
Gemfibrozil 600 MG: Gemfibrozil capsules (600 mg) taken twice per day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Microcrystalline cellulose powder packaged in capsules identical to the experimental condition&#xD;
Placebo oral capsule: Microcrystalline cellulose powder packaged in capsules identical to the experimental medication</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Days Abstinent</title>
          <description>Percentage of days of abstinence from alcohol</description>
          <population>The one participant in the placebo condition dropped out before taking any medication</population>
          <units>Percentage of abstinent days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="0" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Gemfibrozil</title>
          <description>Gemfibrozil 600 mg by mouth twice daily&#xD;
Gemfibrozil 600 MG: Gemfibrozil capsules (600 mg) taken twice per day</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Microcrystalline cellulose powder packaged in capsules identical to the experimental condition&#xD;
Placebo oral capsule: Microcrystalline cellulose powder packaged in capsules identical to the experimental medication</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Eric Claus</name_or_title>
      <organization>The Mind Research Network</organization>
      <phone>5055151556</phone>
      <email>eclaus@mrn.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

